Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome-Reference-Cited by-同舟云学术

Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

Published:2017-09 Issue: Volume:334 Page:142-154
ISSN:0166-4328
Container-title:Behavioural Brain Research
language:en
Short-container-title:Behavioural Brain Research

Author:

Corrales Andrea,Parisotto Eduardo B.,Vidal Verónica,García-Cerro Susana,Lantigua Sara,Diego Marian,Wilhem Filho Danilo,Sanchez-Barceló Emilio J.,Martínez-Cué Carmen,Rueda Noemí

Publisher

Elsevier BV

Subject

Behavioral Neuroscience

Reference93 articles.

1. Mouse models of down syndrome as a tool to unravel the causes of mental disabilities;Rueda;Neural Plast.,2012

2. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for down syndrome;Bianchi;J. Neurosci.,2010

3. Is it possible to improve neurodevelopmental abnormalities in down syndrome?;Bartesaghi;Rev. Neurosci.,2011

4. Trisomy 21 and early brain development;Haydar;Trends Neurosci.,2012

5. Antioxidants in down syndrome;Lott;Biochim. Biophys. Acta,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of the Neurogenic Potential of Melatonin for Treating Neurological and Neuropsychiatric Disorders;International Journal of Molecular Sciences;2023-03-02

2. Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges;Cells;2023-02-07

3. Mitochondrial Dysfunction in Down Syndrome: From Pathology to Therapy;Neuroscience;2023-02

4. Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome;Antioxidants;2022-12-09

5. The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives;Frontiers in Cellular Neuroscience;2022-05-11